

Resource Summary Report

Generated by T1D on Aug 28, 2026

Foundation Medicine

RRID:SCR_025628

Type: Tool

Proper Citation

Foundation Medicine (RRID:SCR_025628)

Resource Information

URL: <https://www.foundationmedicine.com/>

Proper Citation: Foundation Medicine (RRID:SCR_025628)

Description: American company based in Cambridge, Massachusetts, which develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas. Specializes in precision medicine. FMI routinely analyzes cancer specimens using advanced sequencing technology of FoundationOne to profile tumor genomics.

Abbreviations: FMI

Synonyms: Inc., Foundation Medicine

Resource Type: commercial organization

Keywords: genomic profiling assays, next-generation sequencing technology, solid tumors, hematologic malignancies, sarcomas, profile tumor genomics,

Resource Name: Foundation Medicine

Resource ID: SCR_025628

Record Creation Time: 20240816T053258+0000

Record Last Update: 20260815T183217+0000

Ratings and Alerts

No rating or validation information has been found for Foundation Medicine.

No alerts have been found for Foundation Medicine.

Data and Source Information

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Gensheimer MF, et al. (2026) Creating strong predictive models in oncology. *Patterns* (New York, N.Y.), 7(2), 101492.

Liang J, et al. (2026) Loss of luminal lineage drives resistance to next-generation ER?? antagonists in pretreated ER+ HER2- locally-advanced or metastatic breast cancer. *Nature communications*, 17(1).

Yemelyanenko J, et al. (2026) C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3. *Cancer research*, 86(6), 1372.

Millan B, et al. (2025) Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance. *Current oncology* (Toronto, Ont.), 32(6).

Pietrantonio F, et al. (2025) The Prostaglandin EP4 Antagonist Vorbipirant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(4), 649.

Jackson H, et al. (2025) MarkerDB 2.0: a comprehensive molecular biomarker database for 2025. *Nucleic acids research*, 53(D1), D1415.

Li W, et al. (2025) Analytical validation of a homologous recombination deficiency signature (HRDsig) in pan-tumor tissue samples. *PloS one*, 20(11), e0336940.

Nikanjam M, et al. (2025) Novel clinical trial designs emerging from the molecular reclassification of cancer. *CA: a cancer journal for clinicians*, 75(3), 243.

Louie BH, et al. (2024) Molecular Tumor Board for Unicorns: Outcomes for rare and ultra-rare cancers using an N-of-One personalized treatment strategy. *iScience*, 27(8), 110465.

Mostafa G, et al. (2024) The power of deep learning in simplifying feature selection for hepatocellular carcinoma: a review. *BMC medical informatics and decision making*, 24(1), 287.

Martini G, et al. (2023) Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial. *Frontiers in oncology*, 13, 1069370.

Persha HE, et al. (2022) Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response. *Journal of hematology & oncology*, 15(1), 119.

Cheng S, et al. (2022) Utilizing Liquid Biopsy for Treatment Management in Bone-Dominant Metastatic Breast Cancer: A Case Report. *Case reports in oncology*, 15(3), 854.

Akhoundova D, et al. (2022) Targeting ALK in Neuroendocrine Tumors of the Lung. *Frontiers in oncology*, 12, 911294.